European Primary Care Cardiovascular Society
EAS 2019 Emerging evidence reveals that "HDL" represents an enormously heterogeneous mixture of particles, with varying structural, compositional, metabolic and functional properties.
EAS 2019 Prof. Kausik Ray talks about the Familial Hypercholesterolemia Studies Collaboration, which was established to address the unmet need to influence global policy change regarding screening for FH patients early in life.
Observational population-based study suggests that continuing statin therapy after the age of 75 years may reduce CV risk in persons taking the medication for primary prevention.
Adults with clinically normal risk factor profiles, who were randomized to a 25% calorie restriction intervention for 2 years, showed improved insulin sensitivity and metabolic syndrome scores.
In a large cohort study of 1.3 million participants, both systolic and diastolic hypertension were associated with composite of MI, ischemic stroke and hemorrhagic stroke, independent of thresholds defining hypertension.
The new, interactive online tool U-Prevent helps to translate trial data to information relevant to the individual patient: which treatment gives the greatest health benefits?
In a meta-analysis of 21 RCTs including diverse populations, supplementation with vitamin D did not result in a reduction of MACE, MI, stroke/CVA, CV mortality and all-cause mortality compared to placebo.
In the SMART population, smoking cessation after an event resulted in about 5 years longer survival and delay of recurrent events by about 10 years, compared to those who continue to smoke.
EuroPrevent 2019 Prof. Hobbs emphasizes the relevance of targeting CVD prevention in diabetic patients and discusses how can we modify CVD risk factors in these patients.
EuroPrevent 2019 Prof. Jacobs discusses the shift in management of diabetes based on CVOTs and explains underlying mechanisms of benefits with GLP-1RAs in diabetic patients.
The European Association of Preventive Cardiology reviewed various online risk prediction algorithms and considers advantages and caveats, and gives guidance on which tool to use for which patient.
EuroPrevent 2019 Prof. Deanfield reflects on a new era in CVD prevention for patients with diabetes. He discusses how can we prevent diabetes and manage diabetes exposure in the general population.